Новые перспективы применения препарата Кадсила® при раке молочной железы

Как известно, HER-2-экспрессирующий биологический подтип рака молочной железы (РМЖ) характеризуется агрессивным течением и имеет плохой прогноз при отсутствии специфического лечения. До появления трастузумаба 5-летняя общая выживаемость больных распространенными формами РМЖ составляла 20 % (медиана выживаемости 16–29 мес), из которых только 2–5 % имели долгосрочное выживание. Добавление трастузумаба, гуманизированного моноклонального антитела, которое избирательно связывается с рецептором HER-2 на поверхности опухолевых клеток, к химиотерапии 1-й линии HER-2-позитивного метастатического РМЖ привело к значительному повышению эффективности лечения. При добавлении трастузумаба к химиотерапии метастатического РМЖ медиана выживаемости без прогрессирования и общая выживаемость составляют 7,4 мес (4,6 мес без трастузумаба) и 25,1 мес (20,3 мес без трастузумаба) соответственно. Кадсила® (Т-DM1) – конъюгат антитела и лекарственного препарата, реализует новый подход к лечению HER-2-позитивного метастатического РМЖ. Т-DM1 характеризуется инновационным и избирательным механизмом действия на HER-2-положительные опухолевые клетки. С помощью этого механизма Т-DM1 приводит к двойному противоопухолевому эффекту: анти-HER-2 (опосредованному трастузумабом) и цитотоксическому (благодаря селективному транспорту мощного антимитотического агента DM1 в цитоплазму). Данный механизм действия повышает эффективность противоопухолевой терапии, уменьшая при этом токсичность. Препарат Кадсила® одобрен в Российской Федерации, Европейским агентством по лекарственным средствам (European Medicines Agency) и Управлением по контролю за продуктами и лекарствами США (Food and Drug Administration) в качестве монотерапии для лечения больных с HER-2-положительным неоперабельным местно-распространенным или метастатическим РМЖ, которые ранее получали таксаны и / или трастузумаб.

1. Giordano S.H., Temin S., Kirshner J.J. et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32:2078–99.

2. Figueroa-Magalhaes M.C., Jelovac D., Connolly R.M., Wolff A.C. Treatment of HER-2-positive breast cancer. Breast 2014;23:128–36.

3. Krop I., Winer E.P. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2- positive breast cancer. Clin Cancer Res 2014;20:15–20.

4. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127–37.

5. Dawood S., Broglio K., Buzdar A.U. et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010;28:92–8.

6. Azim H., Azim H.A. Jr. Targeting Her-2/neu in breast cancer: as easy as this! Oncology 2008;74:150–7.

7. Prat A., Parker J.S., Karginova O. et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.

8. Perou C.M., Parker J.S., Prat A. et al. Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol 2010;11:718–9.

9. Wolff A.C., Hammond M.E., Schwartz J.N. et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18–43.

10. Ross J.S., Fletcher J.A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998;3:237–52.

11. Slamon D.J., Leyland-Jones B., Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med 2001;344:783–92.

12. Slamon D.J., Clark G.M., Wong S.G. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 1987;235:177–82.

13. Cardoso F., Castiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20:15–8.

14. Menard S., Tagliabue E., Campiglio M., Pupa S.M. Role of HER-2 gene overexpression in breast carcinoma. J Cell Pysiol 2000;182:150–62.

15. Sliwkowski M.X. Ready to partner. Nat Struct Biol 2003;10:158–9.

16. Arpino G., Gutierrez C., Weiss H. et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 2007;99:694–705.

17. Chang J.C. HER-2 inhibition: from discovery to clinical practice. Clin Cancer Res 2007;13:1–3.

18. Bartsch R., Frings S., Marty M. et al. Present and future breast cancer anagementbench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. Ann Oncol 2014;25: 773–80.

19. Marty M., Cognetti F., Maraninchi D. et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265–74.

20. Lambert J.M., Chari R.J. Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem 2014;57(16):6949–64.

21. Lewis P., Phillips G.D., Li G. et al. Targeting HER-2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280–90.

22. Amiri-Kordestani L., Blumenthal G.M., Xu Q.C. et al. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER-2-positive metastatic breast cancer. Clin Cancer Res 2014;20(17):4436–41.

23. Peddi P.F., Hurvitz S.A. Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. Future Oncol 2013;9:319–26.

24. Scaltriti M., Rojo F., Ocana A. et al. Expression of p95 HER-2, a truncated form of the HER-2 receptor, and response to anti-HER-2 therapies in breast cancer. J Natl Cancer Inst 2007;99:628–38.

25. Molina M.A., Codony-Servat J., Albanell J. et al. Trastuzumab (herceptin), a humanized anti-Her-2 receptor monoclonal antibody, inhibits basal and activated HER-2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;61:4744–9.

26. Baselga J., Norton L., Albanell J. et al. Recombinant humanized anti-HER-2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER-2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58: 2825–31.

27. Diessner J., Bruttel V., Stein R.G. et al. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell Death Dis 2014;5:e1149.

28. Junttila T.T., Li G., Parsons K. et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011;128:347–56.

29. Kovtun Y.V., Audette C.A., Mayo M.F. et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010;70:2528–37.

30. Baron J.M., Boster B.L., Barnett C.M. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. J Oncol Pharm Pract 2014;21(2):132–42.

31. Boyraz B., Sendur M.A., Aksoy S. et al. Trastuzumab emtansine (T-DM1) for HER2- positive breast cancer. Curr Med Res Opin 2013;29:405–14.

32. Krop I.E., Elias M.S., LoRusso P.M. et al. A dose-escalation study of trastuzumab-DM1 (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive, locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumabcontaining regimen. Cancer Res 2010;30:2.

33. Miller K.D., Dieras V., Harbeck N. et al. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J Clin Oncol 2014;32:1437–44.

34. Verma S., Miles D., Gianni L. et al. Trastuzumab emtansine for HER-2-positive advanced breast cancer. N Engl J Med 2012;367:1783–91.

35. Welslau M., Dieras V., Sohn J.H. et al. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer 2014;120:642–51.

36. Krop I.E., Lin N.U., Blackwell K. et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER-2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol 2015;26:113–9.

37. Krop I.E., Kim S.B., Gonzalez-Martin A. et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:689–99.

38. Семиглазов В.Ф., Палтуев Р.М., Манихас А.Г. и др. Клинические рекомендации Российского общества онкомаммологов по лечению метастатического РМЖ. 2014. Доступно по: http://www.breastcancersociety.ru. [Semiglazov V.F., Paltuev R.M., Manikhas A.G. et al. Climical practice guidelines of Russian Society of Oncomammology for treatment of metastatic breast cancer. 2014. Available at: http://www.breastcancersociety.ru. (In Russ.)].

39. Болотина Л.В., Зикиряходжаев А.Д., Малыгин С.Е. и др. Клинические рекомендации по диагностике и лечению больных раком молочной железы. Ассоциация онкологов России. М., 2014. 51 с. [Bolotina L.V., Zikiryakhodzhaev A.D., Malygin S.E. et al. Clinical practice guidelines for diagnosis and treatment of breast cancer patients. Russian Society of Oncologists. Moscow, 2014. 51 p. (In Russ.)].

40. Giordano S.H., Temin S., Kirshner J.J. et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32(19):2078–99.

41. Cardoso F., Costa A., Norton L. et al. ESO-ESMO 2nd International consensus guidelines for advanced breast cancer (ABC2).Breast 2014;23(5):489–502.

42. Gradishar W.J., Anderson B.O., Balassanian R. et al. Breast Cancer Version 2.2015. J Natl Compr Canc Netw 2015;13(4):448–75.

43. http://www.agoonline.de/fileadmin/downloads/leitlinien/mamma/maerz2015/en/2015E_20_Cytotoxic_Therapy_in_MBC.pdf.

44. Barok M., Joensuu H., Isola J. Tarstuzumab emtansine: mechanism of action and drug resistance. Breast Cancer Res 2014;16:209.

45. http://clinicaltrials.gov/ct2/show/NCT02073916?term=NCT02073916&rank=1.

46. http://clinicaltrials.gov/ct2/show/NCT02073487?term=NCT02073487&rank=1.

47. Lianos G.D., Vlachos K., Zoras O. et al. Potential of antibody-drug conjugates and novel therapeutics in breast cancer management. Onco Targets Ther 2014;7: 491–500.

48. Swain S., Baselga J., Kim S.-B. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2015;372:724–34.

49. http://dx.doi.org/10.1016/j.critrevonc.2015.08.011.